Plasma N-terminal pro-brain natriuretic peptide levels predict new-onset atrial fibrillation in patients with acute myocardial infarction

Dorje, Tashi; Wang, Xiangfei; Shao, Mian; Zhou, Jingmin; Cui, Xiaotong; Zhang, Feng; Qian, Juying

doi:10.1016/j.ijcard.2013.04.032

Cited by 12 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies had no data on preprocedural NT-proBNP levels. The foregoing studies were all excluded, and six observational studies [6][7][8][9]16,17] were finally included in our meta-analysis ( Figure 1). As a result, a total of 5861 patients were involved in our review: 438 in the new-onset AF group, and 5423 in the no-AF group.…”

Section: Resultsmentioning

confidence: 99%

“…We subsequently performed sensitivity analyses in order to identify the origin of this heterogeneity [12]. As shown in Figure 3, after excluding the studies by Dorje et al [16] and Hwang et al [9] the heterogeneity test showed no significant effects on the results (p ¼ 0.66; I 2 ¼ 0%), whereas the SMD in the NT-proBNP levels between the patients with and without AF was 0.42 units (95% CI 0.31-0.52), the z-score for overall effect was 7.66 (p < 0.00001).…”

Section: Resultsmentioning

confidence: 99%

“…To our knowledge, the studies by Dorje et al [16] and Hwang et al [9] have small sample sizes and study on the populations of Asian (China and South Korea) which were different from the remaining four studies and may be a possible source of heterogeneity.…”

Section: Scandinavian Journal Of Clinical and Laboratory Investigationmentioning

confidence: 85%

“…Because this test has poor power in the event of few studies, we considered both the presence of significant heterogeneity at the 10% level of significance and values of I 2 exceeding 56% as an indicator of significant heterogeneity [14], so that a pooled effect could be calculated with a random-effects model that was used to take into account within-study and between-study variance, or otherwise, with a fixed-effects model. To explore sources of [16] Case-control study * * * * * * * 7 Hwang et al [9] Case-control study * * * * * * * 7 Parashar et al [17] Cohort study * * * * * * * * 8 Guenancia et al [8] Case-control study * * * * * * 6 Gal et al [7] Case-control study * * * * * * * * 8 *The Newcastle-Ottawa Scale criteria are listed in supplemental files. heterogeneity, we performed several sensitivity analyses.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis

Gao

Zeng

Liao

et al. 2016

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Scandinavian Journal Of Clinical and Laboratory Investigationmentioning

confidence: 85%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis

Gao

Zeng

Liao

et al. 2016

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…Though interesting, the clinical utility of this association is uncertain as the authors separated the values into deciles, but did not provide the actual values for these deciles. Two single site studies listed in Table 2 also found a correlation between NAF and higher levels of BNP [59, 60], however, this could be confounded by the fact that AF tends to occur in sicker patients rather than AF leading directly to worse outcomes.…”

Section: Predicting Those With Acs Who Will Develop Afmentioning

confidence: 99%

A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome

Kea

Alligood

Manning

et al. 2016

Curr Emerg Hosp Med Rep

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common arrhythmia encountered by clinicians. Clinical decision-making focuses on reducing ischemic stroke risk in AF patients; however, AF is also associated with an increased risk of acute coronary syndromes (ACS). Patients with ACS and concurrent AF are less likely to receive appropriate therapies and more likely to experience adverse outcomes than ACS patients in sinus rhythm (SR). Clinicians may be able to stratify ACS patients at increased risk of AF development based on clinical characteristics. Evidence supporting specific therapeutic options for prevention of ACS in AF patients or for prevention of AF in ACS patients is limited, however there is some evidence of differing effects among oral anticoagulant regimens in these populations. Investigations of the relationship of AF with the full spectrum of ACS are not well described and should be the focus of future research.

show abstract

Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction

Liu,

Chen,

Pan

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsThe prognostic significance of N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) in heart failure with preserved ejection fraction (HFpEF) has been well established. HFpEF and atrial fibrillation (AF) commonly coexist, and each contributes to poor outcomes independently. Nevertheless, the ability of NT‐proBNP to predict AF in HFpEF patients remains uncertain.Methods and resultsA total of 367 HFpEF patients without baseline AF from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial were included. The Cox proportional hazard model was used to assess the association of NT‐proBNP with the risk of AF. The C‐statistic, categorical net reclassification index (NRI), and integrated discrimination improvement (IDI) were used to evaluate the ability of NT‐proBNP in new‐onset AF prediction. During a median follow‐up of 2.91 years, 17 (4.63%) new‐onset AF cases occurred. Every 1000 pg/mL increase in NT‐proBNP was associated with a 16% increase in the risk of AF occurrence after adjustments (hazard ratio, 1.16 [95% CI, 1.02–1.32]). NT‐proBNP showed a moderate performance for new‐onset AF at 3 years (C‐statistic, 0.67). Adding NT‐proBNP to CHADS2/R2CHADS2/CHA2DS2‐VASc/C2HSET scores improved their predictive performance for AF risk (CHADS2: C‐statistic, 0.63, CHADS2+NT: C‐statistic, 0.69, NRI, 47.46%, IDI, 1.18%; R2CHADS2: C‐statistic, 0.65, R2CHADS2+NT: C‐statistic, 0.70, NRI, 48.03%, IDI, 0.51%; CHA2DS2‐VASc: C‐statistic, 0.67, CHA2DS2‐VASc+NT: C‐statistic, 0.72, NRI, 49.41%, IDI, 0.86%; C2HSET: C‐statistic, 0.77, C2HSET+NT: C‐statistic, 0.80, NRI, 50.32%, IDI, 1.58%).ConclusionsAmong patients with HFpEF, the NT‐proBNP level was positively associated with the incidence of new‐onset AF and may be a promising predictor.

show abstract

Plasma N-terminal pro-brain natriuretic peptide levels predict new-onset atrial fibrillation in patients with acute myocardial infarction

Cited by 12 publications

References 11 publications

Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis

Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis

A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome

Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction

Contact Info

Product

Resources

About